{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T02:26:08Z","timestamp":1782440768095,"version":"3.54.5"},"reference-count":65,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T00:00:00Z","timestamp":1645574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Small bowel adenocarcinoma (SBA) is diagnosed at an advanced (unresectable or metastatic) tumor stage in approximately one-third of cases. This is partly due to the non-specific symptomatology and limitations in endoscopic and radiologic detection methods. In this context, the prognosis remains poor and systemic chemotherapy appears to benefit patients when compared to best supportive care alone, despite the absence of randomized controlled trials. The results of a recent large prospective cohort (ARCAD-NADEGE) reported that the absence of chemotherapy was a predictive factor for a lower overall survival (OS) even though poor differentiation and SBA associated with Crohn\u2019s disease correlate with poor prognosis. In retrospective series, the median OS ranges from approximately 9 to 18 months with current treatment approaches. A combination of a fluoropyrimidine and oxaliplatin (FOLFOX or CAPOX) appears to be the most utilized and effective first-line chemotherapy regimen. Other front-line alternatives are the combination of 5-FU and cisplatin or fluoropyrimidine and irinotecan (FOLFIRI). In second-line, FOLFIRI is an effective option after progression on platinum-based therapy. Taxane-based therapy appears to be an alternative option, but further evaluation in larger series is needed. To a limited extent, the role of surgical resection for metastatic disease appears to be a valid option, though this approach has not been evaluated in prospective clinical studies. Due to the rareness of the disease, inclusion in clinical trials should be prioritized, and there is hope that targeted therapies and immunotherapy may enter the therapeutic arsenal for these patients.<\/jats:p>","DOI":"10.3390\/cancers14051137","type":"journal-article","created":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T09:34:38Z","timestamp":1645608878000},"page":"1137","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Therapeutic Strategies for Patients with Advanced Small Bowel Adenocarcinoma: Current Knowledge and Perspectives"],"prefix":"10.3390","volume":"14","author":[{"given":"Emilie","family":"Moati","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Digestive Oncology, Institut du Cancer Paris Carpem, Assistance Publique des H\u00f4pitaux de Paris, European Georges Pompidou Hospital, University of Paris, 75015 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Overman","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aziz","family":"Zaanan","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Digestive Oncology, Institut du Cancer Paris Carpem, Assistance Publique des H\u00f4pitaux de Paris, European Georges Pompidou Hospital, University of Paris, 75015 Paris, France"},{"name":"Centre de Recherche des Cordeliers, INSERM UMRS1138, CNRS, Sorbonne Universit\u00e9, USPC, Universit\u00e9 de Paris, Equipe Labellis\u00e9e Ligue Nationale Contre le Cancer, CNRS SNC 5096, 75006 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/nrclinonc.2013.132","article-title":"Small Bowel Adenocarcinomas\u2014Existing Evidence and Evolving Paradigms","volume":"10","author":"Raghav","year":"2013","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1080\/0284186X.2016.1182211","article-title":"Trends in Incidence, Treatment and Survival of Small Bowel Adenocarcinomas between 1999 and 2013: A Population-Based Study in The Netherlands","volume":"55","author":"Bernards","year":"2016","journal-title":"Acta Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.21254","article-title":"Cancer Statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/ijc.32860","article-title":"Small Bowel Adenocarcinoma: Results from a Nationwide Prospective ARCAD-NADEGE Cohort Study of 347 Patients","volume":"147","author":"Aparicio","year":"2020","journal-title":"Int. J. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1002\/(SICI)1097-0142(19991215)86:12<2693::AID-CNCR14>3.0.CO;2-U","article-title":"The American College of Surgeons Commission on Cancer and the American Cancer Society. Adenocarcinoma of the Small Bowel: Review of the National Cancer Data Base, 1985\u20131995","volume":"86","author":"Howe","year":"1999","journal-title":"Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/cncr.20404","article-title":"Adenocarcinoma of the Small Bowel: Presentation, Prognostic Factors, and Outcome of 217 Patients","volume":"101","author":"Dabaja","year":"2004","journal-title":"Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1001\/archsurg.137.5.564","article-title":"Primary Cancers of the Small Bowel: Analysis of Prognostic Factors and Results of Surgical Management","volume":"137","author":"Talamonti","year":"2002","journal-title":"Arch. Surg."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00384-021-04050-1","article-title":"Small Bowel Adenocarcinoma in Crohn\u2019s Disease: A Systematic Review and Meta-Analysis of the Prevalence, Manifestation, Histopathology, and Outcomes","volume":"37","author":"Chin","year":"2022","journal-title":"Int. J. Colorectal Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/01. coc.0000214931.01062.01","article-title":"Natural History and Chemotherapy Effectiveness for Advanced Adenocarcinoma of the Small Bowel: A Retrospective Review of 113 Cases","volume":"29","author":"Fishman","year":"2006","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.clon.2006.12.001","article-title":"Chemotherapy in Small Bowel Adenocarcinoma: 10-Year Experience of the British Columbia Cancer Agency","volume":"19","author":"Czaykowski","year":"2007","journal-title":"Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00432-009-0668-3","article-title":"Adenocarcinoma of the Small Bowel at a Single Korean Institute: Management and Prognosticators","volume":"136","author":"Moon","year":"2010","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Koo, D.H., Yun, S.-C., Hong, Y.S., Ryu, M.-H., Lee, J.-L., Chang, H.-M., Ryoo, B.-Y., Kang, Y.-K., and Kim, T.W. (2011). Systemic Chemotherapy for Treatment of Advanced Small Bowel Adenocarcinoma with Prognostic Factor Analysis: Retrospective Study. BMC Cancer, 11.","DOI":"10.1186\/1471-2407-11-205"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Khan, K., Peckitt, C., Sclafani, F., Watkins, D., Rao, S., Starling, N., Jain, V., Trivedi, S., Stanway, S., and Cunningham, D. (2015). Prognostic Factors and Treatment Outcomes in Patients with Small Bowel Adenocarcinoma (SBA): The Royal Marsden Hospital (RMH) Experience. BMC Cancer, 15.","DOI":"10.1186\/s12885-015-1014-6"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.amjsurg.2009.05.037","article-title":"A Single-Institution Experience with 491 Cases of Small Bowel Adenocarcinoma","volume":"199","author":"Halfdanarson","year":"2010","journal-title":"Am. J. Surg."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1634\/theoncologist.10-2-132","article-title":"Phase II Study of 5-Fluorouracil, Doxorubicin, and Mitomycin C for Metastatic Small Bowel Adenocarcinoma","volume":"10","author":"Gibson","year":"2005","journal-title":"Oncologist"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2008.19.7145","article-title":"Phase II Study of Capecitabine and Oxaliplatin for Advanced Adenocarcinoma of the Small Bowel and Ampulla of Vater","volume":"27","author":"Overman","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/CAD.0b013e328350dd0d","article-title":"A Phase II Study of Modified FOLFOX as First-Line Chemotherapy in Advanced Small Bowel Adenocarcinoma","volume":"23","author":"Xiang","year":"2012","journal-title":"Anticancer Drugs"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s10147-017-1138-6","article-title":"A Phase II Study of 5-Fluorouracil\/L-Leucovorin\/Oxaliplatin (MFOLFOX6) in Japanese Patients with Metastatic or Unresectable Small Bowel Adenocarcinoma","volume":"22","author":"Horimatsu","year":"2017","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/annonc\/mdx688","article-title":"Phase II Study of Nab-Paclitaxel in Refractory Small Bowel Adenocarcinoma and CpG Island Methylator Phenotype (CIMP)-High Colorectal Cancer","volume":"29","author":"Overman","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1002\/cncr.30766","article-title":"North Central Cancer Treatment Group N0543 (Alliance): A Phase 2 Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Patients with Advanced Small Bowel Adenocarcinoma","volume":"123","author":"McWilliams","year":"2017","journal-title":"Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/bjc.1998.523","article-title":"The Royal Marsden Experience of a Small Bowel Adenocarcinoma Treated with Protracted Venous Infusion 5-Fluorouracil","volume":"78","author":"Crawley","year":"1998","journal-title":"Br. J. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1159\/000089678","article-title":"Combination Chemotherapy in Advanced Small Bowel Adenocarcinoma","volume":"69","author":"Locher","year":"2005","journal-title":"Oncology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1002\/cncr.23822","article-title":"Chemotherapy with 5-Fluorouracil and a Platinum Compound Improves Outcomes in Metastatic Small Bowel Adenocarcinoma","volume":"113","author":"Overman","year":"2008","journal-title":"Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/annonc\/mdq038","article-title":"Chemotherapy of Advanced Small-Bowel Adenocarcinoma: A Multicenter AGEO Study","volume":"21","author":"Zaanan","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1002\/cncr.25614","article-title":"Second-Line Chemotherapy with Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI Regimen) in Patients with Advanced Small Bowel Adenocarcinoma after Failure of First-Line Platinum-Based Chemotherapy: A Multicenter AGEO Study","volume":"117","author":"Zaanan","year":"2011","journal-title":"Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1634\/theoncologist.2012-0079","article-title":"Multicenter Retrospective Study of 132 Patients with Unresectable Small Bowel Adenocarcinoma Treated with Chemotherapy","volume":"17","author":"Tsushima","year":"2012","journal-title":"Oncologist"},{"key":"ref_27","first-page":"1242","article-title":"Evaluation of Prognostic Factors and Treatment in Advanced Small Bowel Adenocarcinoma: Report of a Multi-Institutional Experience of Anatolian Society of Medical Oncology (ASMO)","volume":"21","author":"Aydin","year":"2016","journal-title":"J. BUON"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e384","DOI":"10.1634\/theoncologist.2018-0573","article-title":"Retrospective Analysis of Taxane-Based Therapy in Small Bowel Adenocarcinoma","volume":"24","author":"Aldrich","year":"2019","journal-title":"Oncologist"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/sj.bjc.6605449","article-title":"Immunophenotype and Molecular Characterisation of Adenocarcinoma of the Small Intestine","volume":"102","author":"Overman","year":"2010","journal-title":"Br. J. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Amano, T., Iijima, H., Shinzaki, S., Tashiro, T., Iwatani, S., Tani, M., Otake, Y., Yoshihara, T., Sugimoto, A., and Egawa, S. (2021). Vascular Endothelial Growth Factor-A Is an Immunohistochemical Biomarker for the Efficacy of Bevacizumab-Containing Chemotherapy for Duodenal and Jejunal Adenocarcinoma. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08724-5"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.clcc.2016.04.013","article-title":"Evaluation of Bevacizumab in Advanced Small Bowel Adenocarcinoma","volume":"16","author":"Aydin","year":"2017","journal-title":"Clin. Colorectal Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00280-017-3371-0","article-title":"Suggestion of Added Value by Bevacizumab to Chemotherapy in Patients with Unresectable or Recurrent Small Bowel Cancer","volume":"80","author":"Takayoshi","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.3892\/ol.2017.6290","article-title":"Clinical Use of Molecular Targeted Agents for Primary Small Bowel Adenocarcinoma: A Multicenter Retrospective Cohort Study by the Osaka Gut Forum","volume":"14","author":"Hirao","year":"2017","journal-title":"Oncol. Lett."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/cncr.30445","article-title":"Bevacizumab Combined with Capecitabine and Oxaliplatin in Patients with Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater: A Single-Center, Open-Label, Phase 2 Study","volume":"123","author":"Gulhati","year":"2017","journal-title":"Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/sj.bjc.6605898","article-title":"Cetuximab in Small Bowel Adenocarcinoma: A New Friend?","volume":"103","author":"Santini","year":"2010","journal-title":"Br. J. Cancer"},{"key":"ref_36","first-page":"1179554920946693","article-title":"Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma: Myth or Reality?","volume":"14","author":"Zeppola","year":"2020","journal-title":"Clin. Med. Insights Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e16264","DOI":"10.1200\/JCO.2018.36.15_suppl.e16264","article-title":"A Retrospective Study of Anti-EGFR Antibody Therapy in Small Bowel Adenocarcinoma","volume":"36","author":"Serpas","year":"2018","journal-title":"JCO"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"277-e26","DOI":"10.1634\/theoncologist.2017-0568","article-title":"Phase II Study of Panitumumab in RAS Wild-Type Metastatic Adenocarcinoma of Small Bowel or Ampulla of Vater","volume":"23","author":"Gulhati","year":"2018","journal-title":"Oncologist"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.2169\/internalmedicine.8312-16","article-title":"Synchronous Duodenal Cancer and Lung Cancer Harboring an Epidermal Growth Factor Receptor Mutation Treated with Erlotinib and Oral Fluoropyrimidine","volume":"56","author":"Akiyama","year":"2017","journal-title":"Intern. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch Repair Deficiency Predicts Response of Solid Tumors to PD-1 Blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability\/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1158\/1078-0432.CCR-21-0159","article-title":"ZEBRA: A Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small-Bowel Adenocarcinoma","volume":"27","author":"Pedersen","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.gtc.2016.04.004","article-title":"Small Bowel Adenocarcinoma","volume":"45","author":"Aparicio","year":"2016","journal-title":"Gastroenterol. Clin. N. Am."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1001\/jamaoncol.2017.1051","article-title":"Genomic Profiling of Small-Bowel Adenocarcinoma","volume":"3","author":"Schrock","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"983","DOI":"10.6004\/jnccn.2017.0140","article-title":"Neoadjuvant Treatment With Trastuzumab and FOLFOX Induces a Complete Pathologic Response in a Metastatic ERBB2 (HER2)-Amplified Duodenal Cancer","volume":"15","author":"Hamad","year":"2017","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in Patients with TRK Fusion-Positive Solid Tumours: A Pooled Analysis of Three Phase 1\/2 Clinical Trials","volume":"21","author":"Hong","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.6004\/jnccn.2019.0043","article-title":"Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology","volume":"17","author":"Benson","year":"2019","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 Blockade in Tumors with Mismatch-Repair Deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus Chemotherapy versus Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer (KEYNOTE-355): A Randomised, Placebo-Controlled, Double-Blind, Phase 3 Clinical Trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","article-title":"Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-Line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial","volume":"6","author":"Shitara","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of Tumour Mutational Burden with Outcomes in Patients with Advanced Solid Tumours Treated with Pembrolizumab: Prospective Biomarker Analysis of the Multicohort, Open-Label, Phase 2 KEYNOTE-158 Study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.trecan.2021.01.010","article-title":"Gut Microbiota in Cancer Immune Response and Immunotherapy","volume":"7","author":"Zhou","year":"2021","journal-title":"Trends Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41571-020-00462-0","article-title":"Broadening Horizons: The Role of Ferroptosis in Cancer","volume":"18","author":"Chen","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ejso.2018.11.012","article-title":"Resection of Small Bowel Adenocarcinoma Metastases: Results of the ARCAD-NADEGE Cohort Study","volume":"45","author":"Rompteaux","year":"2019","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1080\/0284186X.2018.1433321","article-title":"The Evolving Management of Small Bowel Adenocarcinoma","volume":"57","author":"Rovers","year":"2018","journal-title":"Acta Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/ejso.2001.1196","article-title":"Mucinous Adenocarcinoma of the Small Bowel with Peritoneal Seeding","volume":"28","author":"Marchettini","year":"2002","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/jso.20296","article-title":"Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy for Peritoneal Carcinomatosis from Small Bowel Adenocarcinoma","volume":"91","author":"Jacks","year":"2005","journal-title":"J. Surg. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/jso.21315","article-title":"Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Small Bowel Adenocarcinoma","volume":"100","author":"Chua","year":"2009","journal-title":"J. Surg. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1097\/SLA.0b013e3181d9765d","article-title":"A Comparative Study of Complete Cytoreductive Surgery Plus Intraperitoneal Chemotherapy to Treat Peritoneal Dissemination From Colon, Rectum, Small Bowel, and Nonpseudomyxoma Appendix","volume":"251","author":"Elias","year":"2010","journal-title":"Ann. Surg."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.surg.2015.01.021","article-title":"Peritoneal Metastases from Small Bowel Cancer: Results of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in The Netherlands","volume":"157","author":"Lemmens","year":"2015","journal-title":"Surgery"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1245\/s10434-018-6369-x","article-title":"Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastases From a Small Bowel Adenocarcinoma: Multi-Institutional Experience","volume":"25","author":"Liu","year":"2018","journal-title":"Ann. Surg. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1245\/s10434-015-5056-4","article-title":"Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Dissemination from Small Bowel Malignancy: Results from a Single Specialized Center","volume":"23","author":"Liu","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1177\/000313481307900629","article-title":"Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Small Bowel Adenocarcinoma","volume":"79","author":"Sun","year":"2013","journal-title":"Am. Surg."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1080\/02656736.2016.1266700","article-title":"Treatment of Peritoneal Metastases from Small Bowel Adenocarcinoma","volume":"33","author":"Rovers","year":"2017","journal-title":"Int. J. Hyperth."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/5\/1137\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:26:04Z","timestamp":1760135164000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/5\/1137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,23]]},"references-count":65,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["cancers14051137"],"URL":"https:\/\/doi.org\/10.3390\/cancers14051137","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,23]]}}}